• By ICR Secretariat
• Posted Tuesday, February 7, 2023

Gilead’s CAR T-cell therapy recommended for use across the NHS

https://www.pharmatimes.com/news/gileads_car_t-cell_therapy_recommended_for_use_across_the_nhs_1485911

Treatment involves adult patients with relapsed or refractory diffuse large B-cell lymphoma

Gilead Sciences has announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel) for routine commissioning on the NHS across England.